Targeted Therapy for Skin Malignancies: Basal Cell Carcinoma, Melanoma, and Merkel Cell
By clicking the continue button above, I certify I have read the CME/CE information below.
Release Date: February 6, 2018
Expiration Date: February 6, 2019
Patients may not always be offered the most appropriate single and combination targeted therapies that have been proven effective in clinical trials. Currently available clinical data have practice-changing implications for medical oncologists, dermatologists, and related specialists treating skin malignancies. To stay up to date with the latest data, evidence will be presented related to the role of BRAF inhibition, hedgehog signaling, and immunotherapy in the pathogenesis and treatment of basal cell carcinoma (BCC), melanoma, and Merkel cell cancers. Participants will have the opportunity to consider the potential benefits and side effects, in order to ensure that patients reach or maintain their treatment and quality-of-life goals.
The primary audiences for this activity are
· Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care planning across multiple tumor types
· Oncology nurses, advanced practice nurse (APNs), registered nurses (RNs), and nurse practitioners (NPs); primary point persons for patient management and education
· Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
· Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)
Sanjiv S. Agarwala, MD
Professor & Chief
Hematology & Oncology
St Luke’s Cancer Center & Temple University
Sanjiv Agarwala, MD, is the Chief of Medical Oncology & Hematology at St. Luke’s Cancer Center and Professor of Medicine at Temple University School of Medicine, Philadelphia, PA. Dr. Agarwala is nationally and internationally recognized as an expert in the research and treatment of melanoma and immunotherapy of cancer and has presented and led numerous conferences and meetings across the globe.
Dr. Agarwala received his undergraduate education and medical degree from Bombay University. He completed his medical training through residencies and fellowships at the University of Bombay in India, Otago University in New Zealand, and the University of Pittsburgh in Pennsylvania. Dr. Agarwala has written and contributed to more than 200 publications and book chapters on melanoma, immune-oncology, and other research areas. He is board-certified in oncology, hematology, and internal medicine, as well as an active member of several professional and scientific societies, such as the American Association for Cancer Research, the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Society for Melanoma Research.
Dr. Agarwala has been Principal Investigator for multiple clinical trials involving immunotherapy and targeted therapy for melanoma, head & neck and renal cancers, and other malignancies. As a result of his dedication to melanoma and immunotherapy research, Dr. Agarwala has received several honors, including listings as one of America’s top doctors for cancer and best doctors in the United States.
At the conclusion of this session, participants should be able to demonstrate the ability to:
- Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
- Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize survival in patients with melanoma, basal cell, and Merkel cell carcinomas
- Discuss current recommendations for diagnostic testing for skin cancers to facilitate treatment selection
- Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of skin cancers with attention to cost/benefit and toxicity considerations
- Employ resources to increase patient access and engagement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits TM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.
Total number of CE credits made available at this conference is 1.25 hours (0.125 CEUs).
A statement of credit will be issued only upon receipt of a completed activity evaluation.
This is an application-based activity.
For questions regarding CME/CE credit, the post-test, evaluation, please email firstname.lastname@example.org.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Potomac Center for Medical Education, and Rockpointe Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.1 contact hours. Designated for 0.9 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Sanjiv S. Agarwala, MD: Nothing to disclose
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose
Gary I. Cohen, MD: Speaker’s Bureau: Genzyme, NantHealth; Shareholder: Celgene
Alex Ganetsky, PharmD: Honoraria/Advisory Board: Jazz; Speaker’s Bureau: Amgen, Incyte
The content of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.
Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1.25 hours. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.
Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.